Hemastatx
1019.406.058 · rovalta.com · 25/09/2026
Hemastatx
Financial year 2025 · Closed on 31/12/2025
Overview
Identity
Source · BCE/KBOHemastatx is a Private limited company incorporated in 2025. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Charleroi.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 1019.406.058
- Incorporation
- 30/01/2025
- Legal form
- Private limited company
- Registered office
- Rue Clément Ader 10
6041 Charleroi · WallonieSee on map - Contributed capital
- 1,00 €
- Latest accounts
- 31/12/2025
Financials
Source · NBB, 1 filingTrend over 1 financial year
| 2025 | |
|---|---|
| Income statement | |
| Gross margin | -36,1 k € |
| EBITDA | -113,1 k € |
| Operating result | -285,8 k € |
| Net result | -280,1 k € |
| Balance sheet | |
| Equity | -280,1 k € |
| Total assets | 200,8 k € |
| Cash | 180,8 k € |
| Debts | 480,8 k € |
Board of directors
Source · NBB, accounts to 31/12/20251 active
Active mandates
Other companies at this address
Rue Clément Ader 10 6041 Charleroi| Company | CBE no. |
|---|---|
2 Bridge WL● Active | 1003.906.745 |
3D Fibroscreen● Active | 1022.772.354 |
AdipoPharma Belgique● Active | 1008.146.338 |
ATRYON BELGIUM● Active | 0751.698.530 |
| 0479.250.670 | |
ConvEyXo● Active | 0725.874.259 |
CONVEYXO GROUP● Active | 1016.957.797 |
ELKEDONIA BELGIUM● Active | 1021.635.177 |
ENDO TOOLS THERAPEUTICS● Active | 0807.570.233 |
Enodia Therapeutics Belgium● Active | 1039.324.811 |
EU BIOTECH CAMPUS● Active | 0776.668.706 |
Exo-Harvest● Active | 0803.425.264 |
Immunofusion● Active | 0804.563.629 |
ImmunXperts● Active | 0552.755.587 |
INCHINN THERAPEUTICS● Active | 0799.914.755 |
INSTAR BELGIQUE● Active | 1039.395.085 |
KOKUMA● Active | 0799.078.377 |
LYS MEDICAL● Active | 0688.626.061 |
MILEUTIS● Active | 1011.400.984 |
Nexelis Europe● Active | 0744.498.061 |
Financials
Full financial information
Source · NBB| 2025 | |
|---|---|
| Type of account | Micro model |
| Start of the financial year | 29/01/2025 |
| Closing of the financial year | 31/12/2025 |
| Length of the financial year | 12 months |
| Filing date | 30/07/2026 |
| General meeting | 29/07/2026 |
| Currency of the financial year | EUR |
| NBB quality label | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for 7 daysAnnual accounts filings
Source · NBB, 1 filing| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Micro model | 31/12/2025 | 29/07/2026 | 30/07/2026 | French |
Valuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20251 active
Active mandates
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Other03/02/2025CONSTITUTION
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-280,1 k €
- 30/01/2025IncorporationPrivate limited company